Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure

Nov 09 2025
Convention Center: Room 207, Level 2
5:00 PM - 6:30 PM

World Class Speakers

Harry LA Janssen, MD, PhD, FAASLD
Moderator

Harry LA Janssen, MD, PhD, FAASLD

Erasmus MC, University Medical Center Rotterdam
Barbara Testoni, PhD
Moderator

Barbara Testoni, PhD

Inserm UMR 1350, University of Lyon 1, IHU EVEREST

Description

This session will feature translational and early-phase clinical studies that are advancing the therapeutic landscape for chronic hepatitis B. Highlights include a novel capsid assembly modulator, early stage HBV immune modulation trial, therapeutic vaccines, antisense oligonucleotides in combination with pegylated interferon, and a preclinical study of an epigenetic editing agent demonstrating HBV surface antigen loss through targeted DNA methylation. Together, these studies showcase innovative pathways toward viral suppression and functional cure.
 

Journey Maps

Objectives

  • Describe emerging therapeutic strategies for chronic HBV, including mechanisms targeting capsid assembly, immune restoration, and epigenetic regulation
  • Evaluate novel approaches to HBV including antisense oligonucleotides, monoclonal antibodies, and therapeutic vaccines
  • Interpret preclinical and early-phase trial data to understand their potential impact on future viral hepatitis treatment paradigms